Liraglutide

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

Peter Attia MD

A once-a-day GLP-1 agonist that has already received FDA approval for weight loss.

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

A GLP-1 drug approved for diabetes in 2010 and weight loss in 2014, with a half-life of about 13 hours, leading to 7-10% weight loss.

The Ozempic Expert: Ozempic Transforms Your Gut Microbiome! People Are Being Overdosed On Ozempic!

The Diary Of A CEO

An older generation incretin peptide, part of the same family as Semaglutide, but with lower compliance due to more frequent injections and side effects.

337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more

Peter Attia MD